Document Detail

The role of Beta-blockers as first-line therapy in hypertension.
MedLine Citation:
PMID:  21207202     Owner:  NLM     Status:  MEDLINE    
National and international guidelines still recommend β-blockers (BBs) as first-line agents in uncomplicated prevention of hypertension. However, it has been shown that BBs reduce blood pressure less than other drugs, specifically with regard to central aortic pressure. More importantly, recent meta-analyses have highlighted that in primary prevention BBs are associated with a relatively weak effect in reducing stroke compared to placebo or no treatment and, compared with other drugs, show evidence of a worse cardiovascular outcome. Several reasons might explain their mild cardioprotective effect, such as their unfavorable metabolic properties, a lack of efficacy on left ventricular hypertrophy regression and endothelial dysfunction, and reduced patient compliance. Thus, the available evidence does not support the use of BBs as first-line drugs in the treatment of uncomplicated hypertension. It remains to be determined whether newer BBs, such as nebivolol and carvedilol, will be more effective than older compounds in improving cardiovascular prognosis.
Alberto Ranieri De Caterina; Antonio Maria Leone
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  13     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-24     Completed Date:  2011-08-03     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  147-53     Citation Subset:  IM    
Institute of Cardiology, Catholic University of the Sacred Heart, Policlinico A. Gemelli, Largo A. Gemelli, 8, 00168, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / administration & dosage*
Age Distribution
Antihypertensive Agents / administration & dosage*
Benzopyrans / administration & dosage
Blood Pressure Determination
Carbazoles / administration & dosage
Cardiovascular Diseases / epidemiology,  prevention & control*
Ethanolamines / administration & dosage
Follow-Up Studies
Hypertension / diagnosis,  drug therapy*,  epidemiology
Middle Aged
Primary Prevention / methods
Propanolamines / administration & dosage
Randomized Controlled Trials as Topic
Risk Assessment
Severity of Illness Index
Sex Distribution
Survival Analysis
Treatment Outcome
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Benzopyrans; 0/Carbazoles; 0/Ethanolamines; 0/Propanolamines; 030Y90569U/nebivolol; 0K47UL67F2/carvedilol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Role of Lipoprotein-Associated Phospholipase A(2) as a Marker and Potential Therapeutic Target i...
Next Document:  Protein Content in Diabetes Nutrition Plan.